Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Discovery and validation of PZP as a novel serum biomarker for screening lung adenocarcinoma in type 2 diabetes mellitus patients

Fig. 4

Validation of selected candidate proteins by ELISA analysis. a Correlation between PRM-MS and ELISA assay results for PZP. b Differential expression of PZP in the T2DM + LAC and T2DM groups in the discovery set. c Differential expression of PZP in the T2DM + LAC and T2DM groups in the validation set. d Differential expression of PZP in the T2DM + LAC and T2DM groups in the whole set. e ROC analysis of the diagnostic value of PZP for the detection of LAC in T2DM patients in the whole set

Back to article page
\